LONP1 and B-cell non-Hodgkin lymphoma: As Lonp1 protein levels are increased in malignant lymphoma cells if compared with B cells, and considering that Lonp1 knockdown causes lymphoma cell death, the pharmacological inhibition of Lonp1 by CDDO could represent a promising therapeutic approach for B-cell lymphoma [95].